Narrowing Part D Protected Classes Won’t Be Proposed Again – Tavenner
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS Administrator Tavenner provides public assurances that the agency will not reintroduce a proposal to remove antidepressants, antipsychotics and immunosuppressants from protected status in the Medicare Part D program.
You may also be interested in...
CMS’ Likely Reversal Of Threat To Part D Protected Classes Doesn’t Mean Other Reforms Aren’t Coming
Concerns about reducing patient protections will resonate with the Biden Administration and the Medicare Part D protected classes aren’t major cost drivers anyway, Avalere’s Mendelson says.
Under Pressure, CMS Backs Off New Part D Protected Class Management
Decision in final rule marks a setback in the Trump Administration’s game plan for lowering drug prices. But CMS proceeds with codifying previous guidance allowing step therapy for Part B drugs in Medicare Advantage.
CMS Part D Protected Class Restrictions Drawing Bipartisan Concerns In Congress
Congressional objections to proposal join opposition by patient and physician groups.